Myrobalan Therapeutics Nanjing Co. LTD announced residency at JLABS @ Shanghai

Nanjing, China, May 4, 2023 – Myrobalan Therapeutics Nanjing Co. LTD (‘Myro’) announced today that, effective April 10, 2023, it has become a resident of Johnson & Johnson Innovation – JLABS @ Shanghai (‘JLABS’). The company is working toward developing therapeutics to address the unmet needs and societal burdens posed by neurodegenerative, demyelinating and neuropsychiatric disorders.

Jing Wang, Myro’s CEO, commented: “We are delighted and honored to have been selected by JLABS. Our joining the JLABS community represents a significant milestone for our company in China, and we are confident that it will open up new opportunities for us to connect with investors, collaborators, hospitals, and CROs in Shanghai and beyond. JLABS’ central location in Shanghai will be a major asset for us as we seek to expand our network within the JLABS community and promote more efficient interaction with industry leaders and entrepreneurial programs alike. We are also excited to take advantage of JLABS’ capital-efficient workspace and resources, including mentorship, advisors, and expertise, which will be invaluable as we work toward growing our business in China.”

About Myrobalan Therapeutics Nanjing Co. LTD

Myro is a CNS-focused biotech company that is dedicated to developing first-in-class and best-in-class small molecule therapies for neurodegenerative, demyelinating, and neuropsychiatric diseases, including Alzheimer’s disease, multiple sclerosis, amyotrophic lateral sclerosis, and schizophrenia. Founded by world-renowned KOLs from Harvard Medical School and MIT/Broad Institute, we are leveraging our deep expertise in CNS disease biology, biomarker-guided research, and early clinical development to advance our pipeline of programs targeting demyelination, neuroinflammation, and synaptic modulation.

With a world-class chemistry capacity through our partnership with PharmaBlock, we have built a strong IP portfolio in just 1.5 years of operation, with 5 wholly owned patent applications filed. Our Boston site is deeply engaged with top-tier industrial leaders from global pharma and biotech companies, as well as world-class advisors from top academic labs in the CNS field.

Having completed our seed-round financing in September 2021, we are working toward 3 preclinical candidate nominations in 2023, and 2 IND filings in 2024.

For more information, please visit www.myrotx.com

Media Contact
Spokesperson: Jessica Herbst, Director of Operations
Company Website: www.myrotx.com
Email: jessica.herbst@myrotx.com
Phone: (857) 675-1485